Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.

Pharmaceutical

AI/ML

Health Care

Biotechnology

Iktos

Yann Gaston-Mathe

Jean-Baptiste Chéron

Assif SAID

Ramzi Oueslati

Luidgi Gromat

Guillaume P.

Florian Kasper

Ferhat Attar

Charles-Henry Dion

Marion Laguette

Nicolas Martin, PharmD PhD

Quentin Perron

Nicolas Do Huu, PhD

Stéphane MILOT

Jean-Christophe Meillon

Franck Le Vaillant

Alexis Denis

El Gasser Abderraouf

Scientific Research Team

Leadership Team

Software Development Team

Business Development Team

Engineering and Technology

Teams at Iktos

Scientific Research Team

Leadership Team

Software Development Team

Business Development Team

Engineering and Technology